Overview
OSTX market data
Price History
OSTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.98 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.42 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.15 – $2.57 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $74.2M · P/B 112.02.
Company News
FDA Grants OS Therapies’ Requested Type C Statistical Methods Meeting To Review 2.5-Yr Overall Survival Data From Phase 2b Trial Of OST-HER2 In Prevention Of Recurrence In Pulmonary Metastatic Osteosarcoma; Meeting To Occur In Mid-SeptemberBenzinga · Aug 13, 2026, 12:49 PM
8-K filing — OS Therapies Inc (OSTX)SEC EDGAR · Aug 12, 2026, 8:56 PM
OS Therapies Terminates At Market Issuance Sales Agreement On July 23; Co. Announces Termination Of Sales Agreement Effective July 28Benzinga · Jul 29, 2026, 9:14 PM
Roth Capital Initiates Coverage On OS Therapies with Buy Rating, Announces Price Target of $7Benzinga · Jul 9, 2026, 2:00 PM
OS Therapies Accepts New FDA Meeting Request For Review Of Pharmacodynamic Response Biomarker DataBenzinga · Jul 8, 2026, 1:15 PM
OS Therapies Expects Phase 3 Study For The OST-HER2 Metastatic Osteosarcoma Program To Begin Near End Of Q3 2026Benzinga · Jul 6, 2026, 1:15 PM
OS Therapies Requests FDA Type B Meeting To Review Its 2.5-Year OST-HER2 Overall Survival Data And To Confirm Alignment That 3-year Overall Survival Data Is A Clinical EndpointBenzinga · Jun 30, 2026, 11:50 AM
OS Therapies Announces Peer-Reviewed Publication Of Data From Its Phase 2 Clinical Trial Of OST-HER2 With Palliative Radiation Therapy To Prevent Amputation In Frontline Canine OsteosarcomaBenzinga · Jun 26, 2026, 11:50 AM
OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory FilingsBenzinga · Jun 2, 2026, 11:26 AM
OS Therapies Announces Its Phase 2b Trial Of OST-HER2 In The Prevention Or Delay Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma Achieved Statistically Significant Benefit For OST-HER2 Treated Patients In Overall Survival At The 2.5-Year MarkBenzinga · Jun 2, 2026, 10:07 AM